Kerrisdale Capital Management was founded in 2009 by its Chief Investment Officer, Sahm Adrangi. While building the firm, Adrangi has taken an active role in each area of its development. Although more than $150 million dollars is currently under Kerrisdale’s management, the firm managed under $1 million when Adrangi first launched it.
While Sahm Adrangi’s short selling results are quite impressive, he is actually better known for publishing research on companies that he thinks the market currently holds misconceptions about. Two types of stocks that he frequently shares his opinions about are under-followed longs and shorts he believes to be over-hyped.
The Securities and Exchange Commission even took enforcement actions against some of the companies that Sahm Adrangi exposed as fraudulent, like ChinaCast Education Corp and China Education Aliiance. He gained a lot of attention after shorting and publicly exposing several of these fraudulent Chinese companies in 2010 and 2011.
So many different companies and industries have been the focus of his research, but Sahm Adrangi’s focus has, in recent years, been on a few sectors that he has expertise in. The biotechnology sector is one of these, and he has released information on Bavarian Nordic, Zafgen, Pulse Biosciences, Unilife and many more. His research is often focused on the development stages of these companies and their future prospects.
Deutsche Bank was the place where Sahm Adrangi began his career in the world of finance. There, he handled loan debt financing, both high-yield an leveraged. He also worked for several years at Longacre Management, the multi-billion-dollar hedge fund.
Adrangi completed his Bachelor of Arts in Economics upon graduating from Yale University. Thanks to the attention he has gained, both from his trading success and from his research, several investment conferencesave given him the opportunity to share his knowledge by speaking to other investors.